Roche to Present Strategies at Drug Design Summit 2014
Advances & Progress in Drug Design
SMi announce that Roche will now be speaking at the 13th annual conference on Advances and Progress in Drug Design
The Advances and Progress in Drug Design conference deals with the latest ideas and developments in tackling important and difficult targets for medical intervention
LONDON, UNITED KINGDOM, November 8, 2013 /EINPresswire.com/ -- SMi are delighted to announce that Roche will now be speaking at the 13th annual conference on Advances and Progress in Drug Design taking place next February in London.— Novartis
Harold Mauser, Computational Medicinal Chemist, Molecular Design and Chemical Biology from Roche will be providing a keynote address into “Hit Finding Strategies for Protease Targets.” Presentation highlights will include an analysis into what methods to apply in focused screening, lessons learned from fragments and unique insights into structure-guided hit optimisation | Download the conference agenda here.
Dr Neil Press, Director GDC from Novartis, who will also be speaking at the conference next February on Solubility-driven optimisation of PDE4 inhibitors, commented:
“The Advances and Progress in Drug Design conference deals with the latest ideas and developments in tackling important and difficult targets for medical intervention. The range of talks, including a focus on fragment based drug discovery, the role of water and new modelling and crystallisation techniques, will be of widespread industry interest. A resurgence of interest in chemically modified proteins and the development of tools for emerging areas such as epigenetics highlights the transformative role that medicinal chemists can have in deconvoluting early biology.”
Other key speakers will include:
John Mathias, Head of Medicinal Chemistry - Inflammation & Remodelling, Pfizer
Sudharsan Sridharan, Scientist, MedImmune
Tom Heightman, Senior Director, Astex Pharmaceuticals
Amaury Ernesto Fernandez-Montalvan, Lab Head, High Throughput Screening, Bayer HealthCare Pharmaceuticals
Karl-Heinz Baringhaus, Site Director, R&D Frankfurt, Sanofi-Aventis
Andreas Kuglstatter, Principle Scientist, Roche Chemische Unternehmungen AG
Paul Labute, CEO, Chemical Computing Group
Andrea Bortolato, Senior Computational Chemistry, Heptares Therapeutics
Paul Brennan, Group Head/PI, Nuffield Department of Medicine
Click here to see full speaker line-up and conference brochure.
The established 13th annual conference will aim to deliver practical solutions to drug discovery challenges, bringing together industry experts to discuss, debate and share ideas and challenges facing the drug design arena.
For further details visit the event homepage at www.drug-design.co.uk
Advances and Progress in Drug Design: Delivering Practical Solutions to Drug Discovery Challenges
17-18 February 2014
Marriott Regents Park Hotel, London UK
www.drug-design.co.uk
Teri Arri
SMi Group Ltd
+44 (0)20 7827 6162
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
